SNGX - Soligenix rises on data from animal study for booster COVID-19 shot

Soligenix (NASDAQ:SNGX), a late-stage biopharmaceutical company, is trading ~9% higher in the pre-market Thursday after announcing data from a booster vaccination study based on its experimental COVID-19 vaccine CiVax involving non-human primates ((NHPs)). In reaction to a booster shot of CiVax, the NHPs, which were double vaccinated seven months ago with an adenovirus COVID-19 vaccine, showed a rapid increase in neutralizing antibody responses against the virus, including Delta and Omicron variants, the company said. The neutralizing antibody levels jumped 27-fold against the original virus and Delta strains within one week of the booster and up to 243-fold by three weeks, according to Soligenix (SNGX). The introduction of a subunit vaccine such as CiVax, “that has been built on years of proven vaccine technology may also encourage the vaccine-hesitant,” Chief Executive Christopher J. Schaber remarked. Read: In August, Soligenix (SNGX) shares surged after the company highlighted pre-clinical data supporting the potential of its multiple filovirus

For further details see:

Soligenix rises on data from animal study for booster COVID-19 shot